Targeting epigenetic reader GAS41
靶向表观遗传阅读器 GAS41
基本信息
- 批准号:10583570
- 负责人:
- 金额:$ 49.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AcetylationAffinityAnimal ModelAntineoplastic AgentsAstrocytomaBeesBindingBiochemicalBiological AssayBiologyBiophysicsCancer BiologyCancer Cell GrowthCancer cell lineCellsChemicalsChromatinClinical TrialsColonDevelopmentDimerizationDoseDrug TargetingEpigenetic ProcessFluorescence PolarizationFoundationsFutureGAS41 geneGenetic TranscriptionGenomicsGlioblastomaGoalsHistone AcetylationHistone H3HistonesHumanInvestigational TherapiesLengthLibrariesLigandsMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of pancreasMeasuresMethodsMichiganNon-Small-Cell Lung CarcinomaOncogenesOncogenicOutcomePlayPost-Translational Protein ProcessingProteinsReaderRegulationReportingResearch PersonnelRoleSeriesStructureStructure-Activity RelationshipTestingUniversitiesX-Ray Crystallographyanalogcancer cellcytotoxicdesigndimerdrug discoveryexperienceexperimental studyhigh throughput screeninghistone modificationin vivoinhibitorknock-downlung cancer cellmeternovelnovel therapeutic interventionprotein protein interactionscreeningsmall moleculesmall molecule inhibitorsmall molecule librariesstructural biologytumortumorigenesis
项目摘要
Abstract
Post-translational modifications on histone proteins play an essential role in regulating chromatin transcription
in human cancers. Histone acetylation is associated with active gene transcription and plays a crucial role in
tumorigenesis. Indeed, small molecules targeting proteins involved in regulation of histone modifications are
being explored as a very promising anti-cancer agents, with a number of compounds currently in clinical trials
(e.g. BRD4 inhibitors). Recently, the YEATS domains have been discovered as novel acetyl-histone reader
domains. GAS41 was originally found to be amplified in 23% glioblastomas and 80% astrocytoma. Emerging
studies strongly implicate GAS41 as an oncogene in Non-Small Cell Lung Cancer (NSCLC). GAS41 is
frequently amplified in NSCLC and knockdown of GAS41 or disruption of the interaction with acetylated
histones suppresses lung cancer cell growth.
We have recently found that GAS41 is a reader of di-acetylated H3 histone. Full-length GAS41 is dimeric in
cells and binds di-acetylated H3 with high affinity. Based on this finding we developed suites of biochemical
assays suitable for characterization of GAS41 protein-protein interactions and identification of small molecule
inhibitors. In this proposal we plan to develop small molecule inhibitors of GAS41 using high throughput
screening (HTS) in CCG at the University of Michigan. Small molecule inhibitors of GAS41 will be validated
and characterized in a series of biochemical and biophysical experiments. Activity of the most potent
compounds will be characterized in cell-based assays to assess the disruption of GAS41 interactions with
chromatin and understand mechanism of action. Selected GAS41 inhibitors will be also profiled in a panel of
lung cancer cell lines. In summary, we expect to identify highly valuable chemical probe compounds targeting
GAS41 protein-protein interactions suitable for mechanistic studies and pave the way towards development of
potent in vivo active GAS41 inhibitors.
摘要
组蛋白的翻译后修饰在染色质转录调控中起着重要的作用
在人类癌症中。组蛋白乙酰化与活跃的基因转录相关,并在基因转录中起着至关重要的作用。
肿瘤发生事实上,靶向参与调节组蛋白修饰的蛋白质的小分子是非常有用的。
作为一种非常有前途的抗癌药物正在探索中,目前有许多化合物正在进行临床试验
(e.g. BRD 4抑制剂)。近年来,YEATS结构域被发现是一种新型的乙酰组蛋白阅读器
域.最初发现GAS 41在23%的胶质母细胞瘤和80%的星形细胞瘤中扩增。新兴
研究强烈暗示GAS 41是非小细胞肺癌(NSCLC)中的癌基因。GAS 41是
在NSCLC中经常扩增,GAS 41敲低或与乙酰化
组蛋白抑制肺癌细胞生长。
我们最近发现GAS 41是双乙酰化H3组蛋白的阅读器。全长GAS 41是二聚体,
细胞并以高亲和力结合二乙酰化的H3。基于这一发现,我们开发了一套生化
适用于表征GAS 41蛋白-蛋白相互作用和鉴定小分子的测定
抑制剂的在本提案中,我们计划使用高通量开发GAS 41的小分子抑制剂
在密歇根大学的CCG中进行HTS筛查。将验证GAS 41的小分子抑制剂
并在一系列生物化学和生物物理实验中表征。最有效的活性
化合物将在基于细胞的测定中表征,以评估GAS 41与
染色质和了解作用机制。选定的GAS 41抑制剂也将在一组
肺癌细胞系。总之,我们期望鉴定出高度有价值的化学探针化合物,
GAS 41蛋白质-蛋白质相互作用适合于机制研究,并为开发
有效的体内活性GAS 41抑制剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tomasz Cierpicki其他文献
Tomasz Cierpicki的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tomasz Cierpicki', 18)}}的其他基金
Development of small molecules targeting Ring1B-Bmi1 E3 ligase in leukemia
开发针对白血病的 Ring1B-Bmi1 E3 连接酶的小分子
- 批准号:
9153143 - 财政年份:2016
- 资助金额:
$ 49.72万 - 项目类别:
Inhibition of CDC25B phosphatase by targeting protein-protein interactions
通过靶向蛋白质-蛋白质相互作用抑制 CDC25B 磷酸酶
- 批准号:
8611254 - 财政年份:2013
- 资助金额:
$ 49.72万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 49.72万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 49.72万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 49.72万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 49.72万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 49.72万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 49.72万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 49.72万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 49.72万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 49.72万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 49.72万 - 项目类别:
Continuing Grant